Unmasking molecular profiles of bladder cancer
Precision medicine is designed to tailor treatments for individual patients by factoring in each person's specific biology and mechanism of disease. This paradigm shifted from a “one size fits all” approach to “personalized and precision care” requires multiple layers of molecular profiling of...
Main Authors: | Xuan-Mei Piao, Young Joon Byun, Wun-Jae Kim, Jayoung Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2018-03-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-59-72.pdf |
Similar Items
-
Advances in urinary biomarker discovery in urological research
by: Jayoung Kim, et al.
Published: (2020-02-01) -
Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates
by: Xuan-Mei Piao, et al.
Published: (2021-09-01) -
Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist
by: Jayoung Kim, et al.
Published: (2020-11-01) -
Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer
by: Ye-Hwan Kim, et al.
Published: (2016-03-01) -
Urinary Markers in Bladder Cancer: An Update
by: Giorgio Santoni, et al.
Published: (2018-09-01)